ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: infliximab

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

Allison Martell & Allison Lampert  |  

TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…

Common Characteristics in RA Patients Who Don’t Respond to Biologics

  |  

At least 6% of patients who used biologic disease-modifying anti-rheumatic drugs (bDMARDs) suffered refractory disease, according to a recent study based on data from the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis.1 This observational study evaluated the extent of biologic refractory rheumatoid arthritis (RA). The study defined biologic refractory disease as occurring in…

MicroOne / shutterstock.com

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Mary Choy, PharmD, BCGP, FASHP  |  

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Shared Decision Making, Good Disease Control Are Key Components of JIA Management

  |  

A group led by Sarah Ringold, MD, MS, assistant professor of rheumatology at Seattle Children’s Hospital, has developed a new guideline intended to provide recommendations for the treatment and monitoring of children with juvenile idiopathic arthritis (JIA) manifesting as non-systemic polyarthritis, sacroiliitis or enthesitis.1,2 Key Updates The new recommendations appear in both Arthritis & Rheumatology…

New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

  |  

As soon as pediatric patients are diagnosed with juvenile idiopathic arthritis (JIA), they should also be screened for uveitis, says ophthalmologist Gary Holland, MD. Otherwise, the University of California, Los Angeles, provider says, “Kids who are diagnosed with JIA may not come to an ophthalmologist until they have vision-limiting complications.” Uveitis is the most common…

kenary820 / shutterstock.com

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Biosimilars: How Do They Affect Patient Care & Safety?

  |  

CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…

Duration & Treatment of Musculoskeletal Symptoms of Immunotherapy-Induced Arthritis

Arthritis Care & Research  |  

A new case series outlines the treatment and duration of symptoms of 10 patients experiencing the musculoskeletal manifestations of immune-related adverse events. Researchers found these symptoms may last for more than a year, but can generally be treated with low to moderate doses of corticosteroids…